Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Queensland Health
Cantor Fitzgerald
Accenture
Daiichi Sankyo
Covington
Johnson and Johnson
US Department of Justice
UBS

Generated: June 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,778,962

« Back to Dashboard

Summary for Patent: 8,778,962
Title:Treatment of solid tumors with rapamycin derivatives
Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
Inventor(s): Lane; Heidi (Basel, CH), O'Reilly; Terence (Basel, CH), Wood; Jeanette Marjorie (Biel-Benken, CH)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:13/546,686
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,778,962
Patent Claims: 1. A method for inhibiting growth of non-malignant solid tumors of the brain in a subject, said method consisting of administering to said subject a therapeutically effective amount of a compound of formula I ##STR00002## wherein R.sub.1 is CH.sub.3, R.sub.2 is --CH.sub.2--CH.sub.2--OH, and X is .dbd.O.

2. The method of claim 1 wherein the compound of formula I is administered at a daily dose range of from about 0.1 to 25 mg, as a single dose or in divided doses.

3. The method of claim 1 wherein the compound of formula I is administered in a unit dosage form of from about 0.05 to 12.5 mg.

4. The method of claim 1 wherein the compound of formula I is administered in a unit dosage form of from about 0.25 to 10 mg.

5. The method of claim 1 wherein the compound of formula I is administered in a unit dosage form of 10 mg.

6. The method of claim 1 wherein the compound of formula I is administered orally.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Teva
Johnson and Johnson
UBS
Citi
Fuji
Cipla
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.